| For: | Aguado C, Maestre UJ, Mielgo-Rubio X. Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast. World J Clin Oncol 2022; 13(9): 758-761 [PMID: 36212602 DOI: 10.5306/wjco.v13.i9.758] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v13/i9/758.htm |
| Number | Citing Articles |
| 1 |
Meng Hu, Congying Zhong, Jiabing Wang, JinQin Chen, Tao Zhou. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1399975
|
| 2 |
Jiarui Zhao, Baiyang Huang, Min Li, Xingpeng Wang, Jingyu Zhu, Kaiyue Wang, Jing Xu, Xiaohan Wang, Menglin Bai, Guoxin Cai. Exploratory Investigation Into Perioperative Treatment Strategies for Potentially Resectable Stage III–N2 Driver Gene–Negative Non–Small Cell Lung Cancer in the Immunotherapy Era. Cancer Medicine 2026; 15(3) doi: 10.1002/cam4.71696
|
| 3 |
Wenyi Liu, Jinming Tang, Xu Li, Lianghui Gong, Desong Yang, Hui Yin, Wenxiang Wang, Baihua Zhang. Reduction in surgical scope after neoadjuvant chemotherapy and immunotherapy for non‑small cell lung cancer. Oncology Letters 2025; 30(5): 1 doi: 10.3892/ol.2025.15247
|
| 4 |
B.P. Keenan, M. Yadav, G. Ansstas, D. Fabrizio, K. Murugesan, M. Montesion, D. Guha Niyogi, I. Mellman, I. Melero. Intratumoral heterogeneity and immunotherapy resistance: clinical implications. Annals of Oncology 2026; 37(3): 314 doi: 10.1016/j.annonc.2025.10.1239
|
